#United States #Boston #Biologics #Surf Bio #SnapShot™

Surf Bio to Exhibit SnapShot™ Technology at PODD 2025

Surf Bio, an innovator in the biopharmaceutical industry, is poised to make waves at the Partnership Opportunities in Drug Delivery (PODD) conference scheduled for October 27-28, 2025, in Boston, Massachusetts. This highly anticipated event will feature Surf Bio’s groundbreaking SnapShot™ technology, which promises to revolutionize how high-dose biologic therapies are delivered.

Presentation Highlights

The company’s CEO, Bryan Mazlish, will lead a presentation titled "Surf SnapShot™ Technology Ultra-Concentrated Subcutaneous Biologics via Standard Manufacturing Processes". Set for 4:30 PM ET on October 27 in Conference Room IB, this session aims to unveil the scientific foundation of SnapShot, along with insights on its in-vitro and in-vivo performance and commercial relevance.

SnapShot is engineered to facilitate the delivery of ultra-high concentrations of monoclonal antibodies (mAbs) and biologic treatments through a single subcutaneous injection using standard autoinjector devices. This system is powered by a proprietary surfactant polymer developed by Surf Bio, enabling concentrations of up to 600 mg/mL and doses reaching 1,000 mg. This innovation addresses a critical challenge in the formulation and delivery of biologics, marking a significant leap forward in therapeutic administration.

Changing the Paradigm of Biologic Therapy Delivery

“Monoclonal antibodies and biologics are at the forefront of medical advancement, but the existing delivery methods often involve cumbersome, time-consuming intravenous infusions,” remarked Bryan Mazlish. “SnapShot enables a revolutionary shift from lengthy IV administrations to swift at-home injections, dramatically enhancing convenience for patients.” This technology aims not only to advance the accessibility and economic viability of biologic treatments but also to elevate the overall patient experience.

PODD 2025 Conference Engagement

Surf Bio is committed to engaging with leaders in the pharmaceutical and biotechnology sectors at the PODD 2025. Throughout the conference, the company will have the opportunity for personalized meetings, facilitating discussions on potential collaborations utilizing the SnapShot platform. These interactions could pave the way for partnerships that further enhance patient care and therapeutic options in the evolving biopharmaceutical landscape.

About Surf Bio

Founded by the pioneers of Bigfoot Biomedical and AGC, Surf Bio leverages pioneering drug delivery technology developed at Stanford University's Appel lab. The firm’s mission is to transform the delivery of antibodies and biologics, ensuring patients have access to effective treatments that are easy to administer. For more information on Surf Bio and the SnapShot technology, visit www.surf.bio.

In an age where decentralized care and patient-centered models are becoming paramount, Surf Bio's SnapShot technology stands at the cusp of a new era in biologic therapies, ready to change how patients receive these vital treatments.